Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2013
Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Efficacy of fosaprepitant combined with tropisetron plus dexamethasone in preventing nausea and emesis during fractionated radiotherapy with weekly cisplatin chemotherapy: interim analysis of a randomized, prospective, clinical trial using competing risk analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Trial
- Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.Clinical pharmacology in drug development · 2022Trial
- Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Trial
- A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Trial
- The impact of NK1 receptor antagonist selection on chemotherapy-related adverse events: a retrospective study of adverse events in paclitaxel or nab-paclitaxel and carboplatin combination therapy with fosnetupitant and aprepitant use.Frontiers in pharmacology · 2026Article
- Netupitant Exhibits Potent Activity onACS infectious diseases · 2025Article
- Prediction of Drug-Drug Interactions for Highly Plasma Protein Bound Compounds.The AAPS journal · 2024Article
- Lessons learned in translating pain knowledge into practice.Pain reports · 2023Article
- Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective.Advances in therapy · 2023Review
- Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.Drug design, development and therapy · 2017Review
- Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2016Review
- Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.Oncotarget · 2016Article
- Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination.Therapeutics and clinical risk management · 2016Review
- Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Drugs · 2015Review
- Netupitant/Palonosetron.Hospital pharmacy · 2015Article
- A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.BioMed research international · 2015Review
- Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Article
- Portuguese consensus on the prevention and treatment of nausea and vomiting induced by cancer treatments.Porto biomedical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNetupitant is a new highly selective neurokinin-1 receptor antagonist being studied for the prevention of nausea and vomiting in patients undergoing chemotherapy. In vitro studies suggest that netupitant inhibits the cytochrome P-450 isoenzyme 3A4 (CYP3A4). Because netupitant may be used with a variety of drugs, which may be substrates of CYP3A4, two studies were designed to establish the potential risk for drug-drug interaction with three different CYP3A4 substrates: midazolam, erythromycin, and dexamethasone.
methodsBoth trials were three-period crossover studies performed in healthy subjects. In the first study, 20 subjects received netupitant and either midazolam or erythromycin. In the second study, 25 subjects received netupitant and dexamethasone. Serial blood samples were collected over the course of the two studies and pharmacokinetic parameters were determined for all analytes.
resultsNetupitant, by inhibiting the CYP3A4, increased the C max and AUCinf of midazolam by 40 and 144 %, respectively, and the C max and AUCinf of erythromycin by 30 %. Netupitant was shown to increase the exposure to dexamethasone in a dose-dependent manner with the mean increase in AUC and C max by 72 and 11 %, respectively, on day 1 and by 138 and 75 %, respectively, on day 4 when co-administered with 300 mg of netupitant.
conclusionsThe results of these studies suggest that netupitant is a moderate inhibitor of CYP3A4 and therefore, co-administration with drugs that are substrates of CYP3A4 may require dose adjustments. Treatments were well tolerated in both studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.